Esperion Therapeutics, Inc. (ESPR)

NASDAQ: ESPR · Real-Time Price · USD
0.8928
+0.0219 (2.51%)
At close: May 8, 2025, 4:00 PM
0.8900
-0.0028 (-0.31%)
After-hours: May 8, 2025, 7:49 PM EDT
2.51%
Market Cap 176.91M
Revenue (ttm) 259.57M
Net Income (ttm) -153.22M
Shares Out 198.15M
EPS (ttm) -0.81
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 10,082,213
Open 0.8839
Previous Close 0.8709
Day's Range 0.8350 - 0.9265
52-Week Range 0.8200 - 3.9400
Beta 0.75
Analysts Buy
Price Target 5.93 (+564.2%)
Earnings Date May 6, 2025

About ESPR

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company’s marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LD... [Read more]

Sector Healthcare
IPO Date Jun 26, 2013
Employees 304
Stock Exchange NASDAQ
Ticker Symbol ESPR
Full Company Profile

Financial Performance

In 2024, Esperion Therapeutics's revenue was $332.31 million, an increase of 185.66% compared to the previous year's $116.33 million. Losses were -$51.75 million, -75.27% less than in 2023.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for ESPR stock is "Buy." The 12-month stock price forecast is $5.93, which is an increase of 564.20% from the latest price.

Price Target
$5.93
(564.20% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANN ARBOR, Mich., May 08, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on May 7, 2025, the Company granted 15 new employees 49,300 restricted stock units (RSUs) under Esperion...

9 hours ago - GlobeNewsWire

Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada

– Esperion to Receive an Upfront Payment, Near-Term Milestones and Tiered Royalties on Product Sales – – Further Expands Global Access to Bempedoic Acid Products and Provides Opportunity to Bring Inno...

19 hours ago - GlobeNewsWire

Esperion Therapeutics, Inc. (ESPR) Q1 2025 Earnings Call Transcript

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q1 2025 Earnings Conference Call May 6, 2025 8:00 AM ET Company Participants Alina Venezia - Director of Investor Relations Sheldon Koenig - President and Ch...

2 days ago - Seeking Alpha

Esperion to Participate in The Citizens Life Sciences Conference

ANN ARBOR, Mich., April 25, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted Citizens Life Sciences Conference on May 8, 2025, a...

13 days ago - GlobeNewsWire

Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025

– Expands Development Portfolio with Introduction of a Novel Program Targeting PSC – – Confirms Highly Specific Allosteric ACLY Inhibitor Shown to Reduce Liver Injury, Inflammation and Fibrosis Across...

14 days ago - GlobeNewsWire

Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025

Highlighting Novel Insights into ATP Citrate Lyase (ACLY) Biology and its Therapeutic Potential in Multiple Life-Threatening Diseases Highlighting Novel Insights into ATP Citrate Lyase (ACLY) Biology ...

4 weeks ago - GlobeNewsWire

Esperion Appoints Robert E. Hoffman to Board of Directors

- Veteran Industry Executive Brings Decades of Financial and Leadership Experience - ANN ARBOR, Mich., April 01, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Rob...

5 weeks ago - GlobeNewsWire

Esperion Therapeutics, Inc. (ESPR) Q4 2024 Earnings Call Transcript

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q4 2024 Earnings Conference Call March 4, 2025 8:00 AM ET Company Participants Alina Venezia - Director of Investor Relations Sheldon Koenig - President and ...

2 months ago - Seeking Alpha

Esperion Reports Fourth Quarter and Full Year 2024 Financial Results

– FY24 Total Revenue Grew 186% Y/Y to $332.3 Million; FY24 U.S. Net Product Revenue Grew 48% Y/Y to $115.7 Million –

2 months ago - GlobeNewsWire

Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia

– Esperion to Receive an Upfront Payment and Near-Term Milestones Along with a Profitable Transfer Price on Product Sales – – Esperion to Receive an Upfront Payment and Near-Term Milestones Along with...

2 months ago - GlobeNewsWire

Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4

ANN ARBOR, Mich., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2024 financial results before the market opens on Tuesday, March 4, 2025.

2 months ago - GlobeNewsWire

Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions

– $150 Million Senior Secured Term Loan Credit Facility and New $100 Million Convertible Note to Repay Significant Portion of Existing $265 Million Convertible Debt –

5 months ago - GlobeNewsWire

Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone +

The 'Undercovered' Dozen series highlights lesser-covered stocks, offering fresh investment ideas and sparking community discussions on their potential. Ubiquiti Inc. shows promise with operational im...

Other symbols: CRDFUIVODDEFLNCGASSHII
5 months ago - Seeking Alpha

Esperion Announces $210 Million Convertible Debt Financing

ANN ARBOR, Mich., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Esperion (the “Company”) (NASDAQ: ESPR) today announced that it entered into privately negotiated exchange and subscription agreements (the “Agreeme...

5 months ago - GlobeNewsWire

Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel

– Esperion to Receive an Upfront Payment and Near-Term Milestones Along with Tiered Royalties on Product Sales – – Israel-Based Commercial Organization Brings Successful Track Record Commercializing P...

5 months ago - GlobeNewsWire

Will The Long Awaited Breakout For Esperion Therapeutics Hold?

Esperion Therapeutics' stock broke out above a year-long trading range, signaling a potential sustainable breakout if support at $3.40 holds. Despite past skepticism and price fades, recent technical ...

5 months ago - Seeking Alpha

Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024

– An Exploratory Analysis Reports Patients with PAD Who Took Bempedoic Acid Were 36% Less Likely to Experience a Major Adverse Limb Event Compared to Placebo –

6 months ago - GlobeNewsWire

Esperion Therapeutics: Growth Initiatives Are Paying Off - Buy

I maintain my buy rating on Esperion Therapeutics due to its strong Q3 2024 financial performance, showcasing consistent revenue growth and market adoption. The Company's aggressive commercialization ...

6 months ago - Seeking Alpha

Esperion Therapeutics, Inc. (ESPR) Q3 2024 Earnings Call Transcript

Esperion Therapeutics, Inc. (ESPR) Q3 2024 Earnings Call Transcript

6 months ago - Seeking Alpha

Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update

– Total Revenue Increased 52% Year-over-Year to $51.6 Million with  U.S. Net Product Revenue of $31.1 Million, Representing 53% Growth –

6 months ago - GlobeNewsWire

Esperion to Participate in Upcoming Jefferies London Healthcare Conference

ANN ARBOR, Mich., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2024 Jefferies London Healthcare Conference on Tuesd...

6 months ago - GlobeNewsWire

Esperion to Report Third Quarter 2024 Financial Results on November 7

ANN ARBOR, Mich., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2024 financial results before the market opens on Thursday, November 7, 2024.

7 months ago - GlobeNewsWire

Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

ANN ARBOR, Mich., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on September 23, 2024, the Company granted one new employee 3,500 restricted stock units (RSUs) under ...

8 months ago - GlobeNewsWire

Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)

– New Additions to Medicare Formularies at Optum/United AARP and CVS/SilverScript Coupled with Humana Provides Access to More Than 65% of Medicare Insured Lives and More Than 92% of Commercially Insur...

8 months ago - GlobeNewsWire

Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference

ANN ARBOR, Mich., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted H.C. Wainwright 26th Annual Global Investment Confer...

9 months ago - GlobeNewsWire